Generics Will Find it Harder to Implement REMS Reforms, AAM Says

Drug Industry Daily
A A
The FDA’s proposed guidance on Risk Evaluation Mitigation Strategies will be much easier for brand-name drugmakers to implement than for generic manufacturers, the Association for Accessible Medicines says.

To View This Article:

Login

Subscribe To Drug Industry Daily